Currently blood-based studies have demonstrated the utility of T cell activation (HLA-DR, CD-38), proliferation (KI-67), and functional (IFN-γ, TNF- α) markers in predicting and monitoring anti-TB drug responses. This evidence concerns the gene MKI67 and tuberculosis.